Codexis (CDXS) Stock Price
Codexis Price
Over the last 19 years Codexis grew revenue by 9.7% annually, reaching 70.39 M USD. For Codexis, the net margin of -62.5% is down versus -20.3% a few years ago. The consensus 12-month price target for Codexis is 7.14 USD, about 344.9% above where the stock trades today. Of 13 analysts, 10 rate the stock a buy — an overall Buy consensus. The stock trades about 64% above its 52-week low.
Codexis stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Codexis over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Codexis stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Codexis's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Codexis Price |
|---|---|
| 8/30/2026 | 1.61 USD |
| 8/28/2026 | 1.62 USD |
| 8/27/2026 | 1.63 USD |
| 8/26/2026 | 1.65 USD |
| 8/25/2026 | 1.68 USD |
| 8/24/2026 | 1.71 USD |
| 8/21/2026 | 1.67 USD |
| 8/20/2026 | 1.58 USD |
| 8/19/2026 | 1.58 USD |
| 8/18/2026 | 1.50 USD |
| 8/17/2026 | 1.59 USD |
| 8/14/2026 | 1.56 USD |
| 8/13/2026 | 1.60 USD |
| 8/12/2026 | 1.60 USD |
| 8/11/2026 | 1.48 USD |
| 8/10/2026 | 1.50 USD |
| 8/7/2026 | 1.47 USD |
| 8/6/2026 | 1.48 USD |
| 8/5/2026 | 1.43 USD |
| 8/4/2026 | 1.49 USD |
| 8/3/2026 | 1.45 USD |
| 7/31/2026 | 1.40 USD |
| 7/30/2026 | 1.48 USD |
| 7/29/2026 | 1.49 USD |
| 7/27/2026 | 1.56 USD |
| 7/23/2026 | 1.99 USD |
| 7/22/2026 | 2.06 USD |
| 7/21/2026 | 2.20 USD |
| 7/20/2026 | 2.21 USD |
| 7/17/2026 | 2.24 USD |
Codexis Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Codexis Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e | 2029e | 2030e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 41.00 | 48.00 | 50.00 | 60.00 | 68.00 | 69.00 | 104.00 | 138.00 | 70.00 | 59.00 | 70.00 | 74.00 | 88.00 | 117.00 | 139.00 | 166.00 |
| 17.14 | 17.07 | 4.17 | 20.00 | 13.33 | 1.47 | 50.72 | 32.69 | -49.28 | -15.71 | 18.64 | 5.71 | 18.92 | 32.95 | 18.80 | 19.42 |
| 85.37 | 81.25 | 70.00 | 78.33 | 76.47 | 79.71 | 78.85 | 72.46 | 81.43 | 72.88 | 87.14 | 87.14 | 87.14 | 87.14 | 87.14 | 87.14 |
| 35.00 | 39.00 | 35.00 | 47.00 | 52.00 | 55.00 | 82.00 | 100.00 | 57.00 | 43.00 | 61.00 | 64.49 | 76.69 | 101.96 | 121.13 | 144.66 |
| -7.00 | -8.00 | -22.00 | -11.00 | -12.00 | -23.00 | -22.00 | -34.00 | -68.00 | -58.00 | -41.00 | -40.00 | -48.00 | -64.00 | -76.00 | -91.00 |
| -17.07 | -16.67 | -44.00 | -18.33 | -17.65 | -33.33 | -21.15 | -24.64 | -97.14 | -98.31 | -58.57 | -54.05 | -54.55 | -54.70 | -54.68 | -54.82 |
| -7.00 | -8.00 | -22.00 | -10.00 | -11.00 | -24.00 | -21.00 | -33.00 | -76.00 | -65.00 | -43.00 | -33.00 | -24.00 | -4.00 | 6.00 | 17.00 |
| -63.16 | 14.29 | 175.00 | -54.55 | 10.00 | 118.18 | -12.50 | 57.14 | 130.30 | -14.47 | -33.85 | -23.26 | -27.27 | -83.33 | -250.00 | 183.33 |
| 39.84 | 41.00 | 50.60 | 53.97 | 58.62 | 60.48 | 64.91 | 65.56 | 69.50 | 81.30 | 90.91 | 90.91 | 90.91 | 90.91 | 90.91 | 90.91 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Codexis generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Codexis retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Codexis's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Codexis has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Codexis's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Codexis stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Codexis Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Codexis business model & stock analysis
Codexis SWOT Analysis
Strengths
Codexis Inc has a strong and experienced management team, enabling effective decision-making and business strategy implementation. The company possesses cutting-edge biotechnology expertise, allowing it to develop innovative and high-quality products. Codexis also has a strong intellectual property portfolio, which provides a competitive advantage in the industry.
Weaknesses
One of the weaknesses of Codexis Inc is its high dependence on a limited number of key customers. This reliance creates vulnerability in case of any disruptions or changes in customers' preferences. The company also faces challenges in effectively managing its research and development costs, as developing new products requires substantial investments.
Opportunities
Codexis Inc has significant opportunities for growth in the expanding biotechnology and pharmaceutical markets. The increasing demand for sustainable and environmentally friendly solutions presents a favorable market for Codexis' biocatalysis technology. The company can also explore strategic partnerships and collaborations to expand its market reach and access new customers.
Threats
One of the potential threats for Codexis Inc is intense competition in the biotechnology industry. Rival companies with similar technologies and product offerings may limit the market share of Codexis. The company also faces regulatory risks, as changes in government regulations and policies related to biotechnology can impact its operations. Additionally, macroeconomic factors such as economic downturns can affect customer spending and demand for Codexis' products.
Codexis Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Codexis Segments
Codexis Revenue by Segment (1/5)
3 Years
5 Years
Max
Details
Codexis Revenue by Segment (2/5)
3 Years
5 Years
Max
Details
Codexis Revenue by Segment (3/5)
3 Years
5 Years
Max
Details
Codexis Revenue by Segment (4/5)
3 Years
5 Years
Max
Details
Codexis Revenue by Segment (5/5)
3 Years
5 Years
Max
Details
Codexis Revenue by Region
3 Years
5 Years
10 Years
Max
Details
Codexis Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Codexis historical P/E ratio, EBIT multiple, and P/S ratio
Codexis annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Codexis shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Current Codexis forecasts and price targets in September 2026
Analyst Price Targets 2026Codexis Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 8/17/2026 | Maintained | Overweight | 50 | |
| 11/22/2024 | Maintained | Overweight | 41 | |
| 11/15/2024 | Maintained | Overweight | 41 | |
| 9/20/2024 | Maintained | Overweight | 41 | |
| 8/29/2024 | Maintained | Overweight | 41 | |
| 8/19/2024 | Downgrade | BuyHold | 72 | |
| 8/9/2024 | Maintained | Overweight | 41 | |
| 5/3/2024 | Maintained | Buy | 72 | |
| 2/29/2024 | Upgrade | HoldBuy | 72 | |
| 11/7/2023 | Downgrade | BuyHold | 72 |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Codexis Earnings Calls
Codexis Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 8/11/2026 | -0.14USD | - | 14.64 MUSD | - | 2026 Q2 |
| 5/7/2026 | -0.15USD | - | 14.73 MUSD | - | 2026 Q1 |
| 3/11/2026 | -0.04USD | - | 36.55 MUSD | - | 2025 Q4 |
| 8/13/2025 | -0.19USD | - | 14.39 MUSD | - | 2025 Q2 |
| 5/2/2024 | -0.19USD | - | 11.74 MUSD | - | 2024 Q1 |
| 2/21/2024 | -0.16USD | - | 17.33 MUSD | - | 2023 Q4 |
| 8/2/2023 | -0.29USD | - | 22.47 MUSD | - | 2023 Q2 |
| 5/3/2023 | -0.34USD | - | 20.02 MUSD | - | 2023 Q1 |
| 2/22/2023 | -0.22USD | - | 29.49 MUSD | - | 2022 Q4 |
| 11/3/2022 | -0.19USD | - | 31.40 MUSD | - | 2022 Q3 |
EESG©
Eulerpool ESG Scorecard© for the Codexis stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Codexis shareholder structure
| % | Name |
|---|---|
13.96147% | |
0.34068% | |
0.25903% | |
0.10972% | |
0.10237% | |
0.07821% |
Codexis Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
15.89% | SEC ↗ | |
15.89% | SEC ↗ | |
11.00% | SEC ↗ | |
9.90% | SEC ↗ | |
9.90% | SEC ↗ | |
9.90% | SEC ↗ | |
8.82% | SEC ↗ | |
8.30% | SEC ↗ | |
7.90% | SEC ↗ | |
7.90% | SEC ↗ |
Codexis Executives and Management Board
13 members · avg. age 62 · 46 % women
Dr. Stephen Dilly (65)
Chairman of the Board, President, Chief Executive Officer · since 2020
3.47 M USD
Management
Mr. Kevin Norrett (52)
Chief Operating Officer
Dr. Alison Moore (58)
Executive Vice President, Chief Technical Officer · since 2020
Ms. Georgia Erbez (58)
Chief Financial Officer
Ms. Carrie Mckim
Investor Relations · since 2023
Board of Directors
Mr. David Smith (65)
Lead Independent Director
Dr. Raymond De Vre (57)
Independent Director
Dr. Rahul Singhvi (60)
Independent Director
Mr. Dennis Wolf (72)
Independent Director
Ms. H. Stewart Parker (69)
Independent Director
Dr. Esther Martinborough (59)
Independent Director
Frequently asked questions about Codexis
The business model of Codexis Inc is focused on providing sustainable biocatalysis solutions to industries such as pharmaceuticals, food and beverage, and chemicals. Codexis employs proprietary protein engineering technology to create highly efficient biocatalysts that can replace traditional chemical processes, resulting in cost savings, increased product yields, and reduced environmental impact. By collaborating with its customers, Codexis develops customized enzymes and processes that address specific challenges and improve overall efficiency in various manufacturing processes. Codexis aims to offer value-added solutions to help its customers achieve their sustainability goals while maintaining profitability.
Codexis Inc is primarily active in the biotechnology industry.
The main competitors of Codexis Inc in the market include companies such as DSM, Ginkgo Bioworks, and Amyris.
Codexis Inc is a leading protein engineering company based in Redwood City, California. Founded in 2002, Codexis specializes in designing and optimizing enzymes for various industries, including pharmaceuticals, food and beverages, and sustainable chemistry. With a strong focus on biocatalysis, the company utilizes its proprietary CodeEvolver® platform to develop customized enzyme solutions that enhance the manufacturing processes of its clients. Over the years, Codexis has established itself as a key player in the biotech industry, collaborating with global partners and attracting numerous high-profile clients. By leveraging its expertise in directed evolution and protein engineering, Codexis continues to drive innovation and provide sustainable solutions to address complex challenges in different sectors. As a leader in the field, Codexis Inc consistently strives to deliver value and impact through the application of biocatalysis and its cutting-edge enzyme technologies.
Codexis Inc has achieved several significant milestones throughout its history. One notable achievement was the commercialization of its proprietary CodeEvolver® protein engineering platform. This innovation enabled the company to develop and optimize bio-based processes for various industries, including pharmaceuticals, food and beverages, and chemicals. Another milestone was when Codexis partnered with leading companies like Merck, GlaxoSmithKline, and Shell, showcasing its reputation as a trusted collaborator. Additionally, the company's successful initial public offering (IPO) in 2010 marked a major milestone, providing Codexis with the financial resources to further expand its cutting-edge biocatalysis technologies. Overall, Codexis Inc has consistently demonstrated industry leadership and achieved significant progress in advancing sustainable solutions.
Codexis Inc is primarily present in the United States.
Codexis Inc represents a strong commitment to innovation and sustainability in the biotechnology industry. The company's corporate philosophy is centered around delivering transformative solutions for its customers and creating value for its stakeholders. Codexis Inc is dedicated to leveraging its proprietary technologies and expertise to develop and commercialize high-performance enzymes and other bio-based products. By harnessing the power of biocatalysis, the company aims to enable more sustainable manufacturing processes across various sectors. Codexis Inc's steadfast dedication to excellence and its focus on delivering sustainable solutions makes it a prominent player in the biotechnology industry.
Analysts currently set an average price target of 6.71 USD for the Codexis stock (median: 7.14 USD), implying +318.4 % versus the latest price. The consensus is based on 13 analyst ratings.
13 analysts currently rate the Codexis stock: 10 recommend buying, 3 holding and 0 selling. For 2026, analysts expect Codexis to generate revenue of 74.09 M USD and earnings per share of -0.36 USD.
Converted at the current exchange rate, the Codexis share trades at 1.38 EUR (1.61 USD).
The Codexis share (CDXS) is listed on 7 stock exchanges, including: NASDAQ (CDXS), Frankfurt (4QK.F), München (4QK.MU), Düsseldorf (4QK.DU), London (0I0X.L), London (0I0X.L), SIX (Zürich) (4QK.SW).
Codexis Inc. is a specialist in enzyme technology, operating since 2002 and based in Redwood City, California. The company's business model includes three main areas: enzyme development, proteins, and research services. By combining its capabilities in enzyme technology and protein engineering, Codexis has created unique solutions tailored to the needs of the biotechnology, chemical, pharmaceutical, and food industries. The core business of Codexis is enzyme development. Codexis manufactures enzymes that help customers improve chemical processes by exhibiting higher activities and selectivities, making the production of chemicals and bioproducts more cost-effective and environmentally friendly. The company has developed a range of enzymes used in industrial biotechnology, including medicines, seed treatments, food and feed additives, as well as detergents and cleaning agents. In addition to enzyme development, Codexis also offers proteins that the company uses for biochemical analysis, diagnostics, and protein production. Another business area of Codexis is the manufacturing of enzymes for use in IVD diagnostics. These enzymes are used in medicine and biotechnology, particularly in clinical diagnostics and quality assurance. Codexis also provides research services based on enzyme and protein engineering solutions. The company's research department specializes in developing high-performance enzymes and proteins that enable a variety of applications. Furthermore, Codexis utilizes its research capabilities to offer contract research services in protein engineering and expression, as well as enzyme screening and optimization. Codexis has also developed fluorescence spectroscopy technology that allows for the real-time measurement of enzyme activity. These advanced enzyme engineering tools are essential for customers looking to optimize their processes and improve cost-effectiveness. In terms of its business model, Codexis generates its revenues primarily through the sale of enzyme products and contract research services. The company also pursues licensing revenue for its technology related to the development and use of enzymes in the industry. The company is committed to maintaining and expanding its competitive position in the field of enzyme and protein engineering technology. Codexis continuously strives to develop promising technologies for its customers and strengthen its research and development in this area. By supporting its customers with its specific, customized solutions and continually investing in research and development, Codexis positions itself as a leading provider of enzyme and protein engineering technologies.
The expected revenue of Codexis is 74.09 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Codexis is -33.12 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Codexis is currently -4.41. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Codexis stock.
The price-to-sales ratio (P/S) of Codexis is currently 1.97. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Codexis stock.
The Eulerpool Quality Score for Codexis is 3/10.
The ISIN of Codexis is US1920051067. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Codexis is A0Q2S4. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Codexis is CDXS. The ticker symbol is used to trade Codexis shares on the stock exchange.
Codexis paid dividends every year for the past 0 years.
Codexis is assigned to the 'Health' sector.
The dividends of Codexis are distributed in USD.
Codexis stock
Codexis Peer Group
Codexis Ticker
Codexis FIGI
All fundamentals and in-depth analysis of Codexis
Our stock analysis for Codexis stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Codexis. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.